ArticleGynecologic oncology reports2026
Complete and durable response to trastuzumab deruxtecan in HER2-amplified invasive vulvar adenocarcinoma: A case report.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vulvar adenocarcinoma represents a rare subset of gynecologic malignancies, with limited therapeutic options in the advanced or recurrent setting. HER2 testing is not routinely performed on vulvar carcinoma. Case presentation: We report the case of a 69-year-old woman diagnosed with human epidermal growth factor 2 (HER2)-amplified recurrent metastatic vulvar adenocarcinoma arising in the context of extramammary Paget's disease. Despite multiple standard systemic therapies, she experienced marked disease with diffuse metastases. With subsequent trastuzumab deruxtecan (T-Dxd) treatment, she achieved a complete and durable response and remains with no evidence of disease after one year of follow-up. Conclusion: This report underscores the potential utility of HER2-directed therapy in select cases of vulvar carcinoma and emphasizes the importance of molecular profiling in rare gynecologic neoplasms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.